| Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma M Atefi, E Avramis, A Lassen, DJL Wong, L Robert, D Foulad, M Cerniglia, ... Clinical cancer research 20 (13), 3446-3457, 2014 | 356 | 2014 |
| Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma DJL Wong, L Robert, MS Atefi, A Lassen, G Avarappatt, M Cerniglia, ... Molecular cancer 13, 1-15, 2014 | 124 | 2014 |
| Gene therapy and targeted toxins for glioma M G Castro, M Candolfi, K M Kroeger, G D King, J F Curtin, K Yagiz, ... Current gene therapy 11 (3), 155-180, 2011 | 118 | 2011 |
| B cells are critical to T-cell—mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma M Candolfi, JF Curtin, K Yagiz, H Assi, MK Wibowo, GE Alzadeh, ... Neoplasia 13 (10), 947-IN23, 2011 | 115 | 2011 |
| Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity M Candolfi, K Yagiz, D Foulad, GE Alzadeh, M Tesarfreund, ... Clinical Cancer Research 15 (13), 4401-4414, 2009 | 113 | 2009 |
| Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics M Candolfi, W Xiong, K Yagiz, C Liu, A Muhammad, M Puntel, D Foulad, ... Proceedings of the National Academy of Sciences 107 (46), 20021-20026, 2010 | 109 | 2010 |
| Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression AKM Ghulam Muhammad, M Candolfi, GD King, K Yagiz, D Foulad, ... Clinical Cancer Research 15 (19), 6113-6127, 2009 | 83 | 2009 |
| Differences in surgical outcomes for patients with craniosynostosis in the US: impact of socioeconomic variables and race F Shweikeh, D Foulad, M Nuño, D Drazin, MA Adamo Journal of Neurosurgery: Pediatrics 17 (1), 27-33, 2016 | 72 | 2016 |
| Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma M Atefi, B Titz, E Avramis, C Ng, DJL Wong, A Lassen, M Cerniglia, ... Molecular cancer 14, 1-12, 2015 | 63 | 2015 |
| Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics M Candolfi, GD King, K Yagiz, JF Curtin, Y Mineharu, AKMG Muhammad, ... Neoplasia 14 (8), 757-IN26, 2012 | 52 | 2012 |
| Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma AKMG Muhammad, M Puntel, M Candolfi, A Salem, K Yagiz, C Farrokhi, ... Clinical Pharmacology & Therapeutics 88 (2), 204-213, 2010 | 44 | 2010 |
| Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation M Candolfi, K M Kroeger, W Xiong, C Liu, M Puntel, K Yagiz, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2011 | 20 | 2011 |
| Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma DJL Wong, L Robert, MS Atefi, A Lassen, G Avarappatt, M Cerniglia, ... Mol Cancer 14 (128), 3, 2015 | 9 | 2015 |
| Evaluation of proapototic transgenes to use in combination with Flt3L in an immune‐stimulatory gene therapy approach for Glioblastoma multiforme (GBM) M Candolfi, GD King, AKMG Muhammad, M Puntel, KM Kroeger, C Liu, ... The FASEB journal 22, 1077.13-1077.13, 2008 | 5 | 2008 |
| Melanomas with rare BRAF mutations and their responses to MAPK pathway blocking drugs. MS Atefi, CP Ng, DJ Wong, L Robert, H Escuin-Ordinas, A Lassen, ... Cancer Research 73 (8_Supplement), 915-915, 2013 | 1 | 2013 |
| Circulating DNA released from brain tumors in response to conditional cytotoxic/immune stimulatory gene therapy induces activation of TLR9 on pDCs, leading to antitumor immunity M Candolfi, K Yagiz, K Balasubramanian, M Puntel, GD King, Y Mineharu, ... Cancer Research 71 (8_Supplement), 467-467, 2011 | 1 | 2011 |
| Glioma-derived factors induce the expansion of myeloid derived suppressor cells which mediate immune suppression and tumor progression M Candolfi, K Yagiz, H Assi, AG Muhammad, C Liu, D Foulad, G Alzadeh, ... Cancer Research 71 (8_Supplement), 3645-3645, 2011 | 1 | 2011 |
| Synergistic antitumor effect of chemotherapy and immunotherapy in syngeneic brain tumor models in mice MG Castro, M Candolfi, K Yagiz, KM Kroeger, D Foulad, GE AhlZadeh, ... Cancer Research 70 (8_Supplement), 3825-3825, 2010 | 1 | 2010 |
| B cells present tumor antigen and mediate anti-tumor immunity induced by a combined immune-stimulatory/conditional cytotoxic therapy for glioblastoma M Candolfi, JF Curtin, K Yagiz, H Assi, M Wibowo, G Ahlzadeh, D Foulad, ... Cancer Research 70 (8_Supplement), 1909-1909, 2010 | 1 | 2010 |
| NOVEL BICISTRONIC HIGH-CAPACITY HELPER-DEPENDENT ADENOVIRAL VECTOR COEXPRESSING FLT3L AND TK (1GCV) INDUCES INTRACRANIAL GBM REGRESSION AND ANTI-GBM IMMUNOLOGICAL MEMORY AKM Muhammad, K Kroeger, M Puntel, M Candolfi, K Yagiz, C Liu, ... NEURO-ONCOLOGY 11 (5), 619-619, 2009 | 1 | 2009 |
